Analys

NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market

Analys, Research

Nanexa’s next proprietary development project, NEX-22, is a long-acting formulation of liraglutide for treatment of type 2 diabetes...

Read More

SWEDISH STIRLING: Strengthens finances with unique climate compensation-linked instrument

Analys, Research

In addition to an annual yield in of 7.25%, Swedish Stirling’s imminent preference rights issue also retain emission rights equal to...

Read More

SIMRIS ALG: Cyano deal jumpstarts venture into Biopharma | See interview with CEO Julian Read

Analys

With the successful completion of the acquisition of Berlin-based Cyano Biotech GmbH, Simris Alg is now set to accelerate their entry into...

Read More

AGTIRA: Another grocery giant in the books

Analys, Research

With a newly signed LOI for an Agtira Greens with Coop Nord, part of Sweden’s second largest grocery group, Agtira can add another...

Read More

BONZUN: Set to refuel to latch on to global DTx trend

Analys

The Q2’22 report showed some continued progress for Bonzun’s stress management service, Bonzun Evolve, with 450 new licenses from KTH...

Read More

QLUCORE: CE headwind overshadows structural growth story

Analys, Research

While the business side of Qlucore is moving steady forward, with 67% growth, two new Qlucore Insight license deals and an expansion of the...

Read More

KEBNI: Strong momentum with near-term triggers to crystalise further upside potential

Analys

Besides completing a capital raise in these challenging market conditions, KebNi enjoys strong business momentum with new antenna orders...

Read More

DLABORATORY: Welcome boost from booming attention on power grid stability

Analys

The rise of network stability and electricity security on the public agenda has finally started to translate into a material rise in...

Read More

HILBERT GROUP: Light at the end of the tunnel | Read our interview with Niclas Sandström, CEO Hilbert Group

Analys, Research

In the first half of 2022 we have seen the collapse of Luna, several big crypto companies struggle and both Bitcoin and Ether price tumble...

Read More

MEDS: Strong momentum in pharmacy market’s transition to online

Analys

With a proprietary tech platform, 80-130% retention rates and a Net Promotor Score (NPS) of 72/100, MEDS is on track to capture the SEK...

Read More

For new research on growth stocks, sign up to our newsletter